#Germany #NMSC #OncoBeta #Rhenium-SCT #Garching

Introduction

OncoBeta GmbH has made significant strides in the field of non-melanoma skin cancer (NMSC) treatment with its innovative epidermal radioisotope therapy, Rhenium-SCT. The company recently announced the 12-month interim results from their EPIC-Skin Study, a multi-centre international Phase IV clinical trial that demonstrated the efficacy and safety of Rhenium-SCT for patients diagnosed with NMSC.

Study Overview

The EPIC-Skin Study aimed to assess the treatment’s effectiveness as well as key patient-reported outcomes pertaining to quality of life, comfort during treatment, and cosmetic appearances. The study included 184 adult patients who had been histologically confirmed with stage I or II NMSC, which encompasses various types like basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The trial spanned across several countries, including Australia, Germany, the UK, and South Africa, showcasing its large-scale and international nature.

Patient Demographics

A median patient age of 70.3 years was observed among participants, with a range extending from 27 to 95 years. Of these patients, a substantial 53.3% were male, and 71.2% had only one lesion treated. Lesions were located predominantly on the head and neck, trunk, and extremities, highlighting the commonality of these cancers in visible areas.

Treatment Methodology

Rhenium-SCT treatment involved a single application of a 50-Gy dosage of Rhenium-188, embedded in a resin, which is applied topically using an adhesive film directly to the lesion site. The effectiveness of the treatment was evaluated based on modified RECIST criteria after 12 months of follow-up, while the quality of life was assessed via the Skin Cancer Index and treatment comfort was rated through questionnaires. Cosmetic results were recognized through visual analogue scale assessments by both patients and clinicians, ensuring comprehensive evaluation of treatment outcomes.

Key Results

The preliminary results from the study are nothing short of remarkable:

• - Overall response rate: 97.3%
• - Complete response rate: 94.1%
• - Partial response rate: 3.2%
• - Mean improvement in quality of life: +10.55 points from baseline
• - Pain/discomfort during treatment: None reported
• - Favorable cosmetic outcomes: Reported by both patients and clinicians
• - Most common adverse effect: Grade 1 hypopigmentation was observed in 60.4% of patients, with no grades above 2 noted.

These figures strongly suggest that Rhenium-SCT not only provides excellent efficacy for NMSC treatment but also positively influences patients' quality of life with minimal adverse effects.

Expert Insights

"Rhenium-SCT has consistently shown effectiveness and safety in previous studies," remarked Dr. Gerhard Dahlhoff, the Medical Director at OncoBeta. The 12-month results bolster the therapy's position as a non-invasive, targeted treatment option especially appreciated by those who prefer to avoid surgical interventions for health or cosmetic reasons. Shannon D. Brown III, CCO and Managing Director for OncoBeta Europe, adds, "These findings highlight our commitment to enhancing patient experiences in tandem with outstanding clinical outcomes."

About Rhenium-SCT

Rhenium-SCT stands out as a painless and non-invasive treatment methodology for non-melanoma skin cancers, which collectively rank as the most prevalent cancer type globally. Utilizing the radioisotope Rhenium-188, this therapy focuses precisely on the targeted lesions while sparing healthy tissue. This innovative approach helps facilitate seamless healing, restoring appearance in treated areas without residual scars.

Company Background

Founded in Germany and headquartered near Munich, OncoBeta is dedicated to developing cutting-edge therapies for skin-related afflictions. The Rhenium-SCT has been a focal point of their commitment towards advanced and personalized treatment solutions in skin cancer. The company's operational strategies align with health, safety, and environmental protection standards, ensuring patients receive top-tier care.

For those interested in more information about Rhenium-SCT, visit OncoBeta's official website and follow them on their social media platforms to stay updated on the latest news and developments in skin cancer treatment.